Anbogen Therapeutics and University of Tokyo team up to evaluate ABT-301 across multiple tumor types, aiming to accelerate clinical indication expansion
Executive summary: Anbogen Therapeutics entered a Collaborative Research Agreement with the Laboratory of Veterinary Surgery at the University of Tokyo to evaluate its drug ABT-301 across multiple tumor types. The partnership aims to produce preclinical data that could support expanded human clinical indications and accelerate development of ABT-301.
Who is involved: Anbogen Therapeutics Inc. (TPEx: 7784) and the University of Tokyo's Laboratory of Veterinary Surgery.
Likely next: Preclinical studies will be conducted under the agreement, with potential IND‑enabling results informing future clinical trial plans.
The agreement combines Anbogen's clinical-stage precision oncology expertise with the University of Tokyo's veterinary surgery laboratory resources to study ABT-301 in various cancer models. By assessing the drug across several tumor types, the collaboration seeks to generate data that could support broader human indications and potentially shorten the path to later-stage trials. No financial terms or timelines were disclosed in the announcement.
Timeline
- — Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion (PR Newswire)
Analysis — what this means
Sectors affected
- Oncology
- Biotechnology
Sources
Related cases
- Sketch leverages its 80% hold on Japan's window coating market to launch UV Shield PU for global expansion
- VMFi’s AI‑powered platform aims to streamline real‑time multilingual communication for global businesses, potentially reducing translation costs and accelerating cross‑border collaboration
- Colleen Conway honored with NAfME Senior Researcher Award for lifetime contributions to music education research
- Dan Ticktum's victory in the inaugural Tokyo night race underscores growing commercial interest in Formula E's expansion into Asian markets
- Germany's youngest AI economics professor urges scrutiny beyond the AI hype, highlighting the need for grounded analysis of AI's economic impact
- Intacture’s underground data centre launches, boosting regional AI‑ready compute capacity